AUG 28·SEC EDGARLow
Tsao David sold $1.0M of BLLN
Tsao David (Chief Technology Officer) sold 10,000 shares of BillionToOne, Inc. (BLLN) at $100.00 ($1.00M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · DIAGNOSTICS & RESEARCH
$BLLN
BillionToOne, Inc.
Price · $BLLNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BLLN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $11.3M 29 txs
Atay Oguzhan24× · $8.5M
10b5-1 share of filings100%
Top stories · $BLLNMore →
AUG 19·prnewswire.com
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
BillionToOne (BLLN) published a study in The Green Journal showing its Unity Fetal Risk Screen, a cfDNA-based test, demonstrated 94.4% sensitivity, 99.5% specificity, and >99.9% negative predictive value in assessing fetal risk for recessive conditions in 2,212 general-risk pregnancies. The study, conducted across nine U.S. institutions, supports the use of cfDNA fetal risk assessment as a primary screen in routine prenatal care, offering advantages over traditional carrier screening.
AUG 12·SEC EDGAR
Tsao David sold $929K of BLLN
Tsao David (Chief Technology Officer) sold 10,000 shares of BillionToOne, Inc. (BLLN) at $92.86 ($0.93M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
BLLN sentiment & insider activity
Recent BLLN coverage spans insider activity, earnings and technology.
In the last 30 days, BLLN insiders filed 29 SEC Form 4 transactions — no purchases and 29 sales ($11.3M). The most active reporter was Atay Oguzhan, Chairman and CEO, with 24 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving BLLN
Insider sale may signal lack of confidence, but size is modest for a microcap.
The study provides strong clinical evidence for the company's Unity Fetal Risk Screen, potentially expanding market adoption.
This is a routine insider sale disclosure with limited signal value because it is explicitly under a pre-arranged 10b5-1 plan.
Analyst target cut and after-hours weakness are the immediate trading signals, while guidance and product roadmap remain intact.
This is a routine, pre-arranged insider sale disclosure; it may slightly affect sentiment but does not signal a new operational or financial change.
alphai scores every news story that mentions BLLN with an AI model for sentiment and relevance, and aggregates insider trades from BillionToOne, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BLLN
Score
Tsao David sold $1.0M of BLLN
Tsao David (Chief Technology Officer) sold 10,000 shares of BillionToOne, Inc. (BLLN) at $100.00 ($1.00M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min read
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
BillionToOne (BLLN) published a study in The Green Journal showing its Unity Fetal Risk Screen, a cfDNA-based test, demonstrated 94.4% sensitivity, 99.5% specificity, and >99.9% negative predictive value in assessing fetal risk for recessive conditions in 2,212 general-risk pregnancies. The study, conducted across nine U.S. institutions, supports the use of cfDNA fetal risk assessment as a primary screen in routine prenatal care, offering advantages over traditional carrier screening.
2 min readTsao David sold $929K of BLLN
Tsao David (Chief Technology Officer) sold 10,000 shares of BillionToOne, Inc. (BLLN) at $92.86 ($0.93M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
2 min readTop diagnostics stock pick from BTIG
BTIG named BillionToOne (BLLN) its top diagnostics pick, reiterating a Buy rating while lowering its price target to $130 from $142. BTIG cited Q2 FY2026 revenue of $109.4M, up 64% YoY, and prenatal volumes of about 181,000. Shares fell 28% after-hours. BTIG noted lower true-ups and a payor-related item, and kept FY2026 guidance at $450M to $465M.
3 min readAtay Oguzhan sold $2.3M of BLLN
Atay Oguzhan (Chairman and CEO) sold 15,539 shares of BillionToOne, Inc. (BLLN) at $150.03 ($2.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min read
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)
BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.
3 min readAtay Oguzhan sold $1.7M of BLLN (indirect holdings)
Atay Oguzhan (Chairman and CEO) sold 12,500 indirectly-held shares of BillionToOne, Inc. (BLLN) at $137.37 ($1.72M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readAtay Oguzhan sold $4.5M of BLLN
Atay Oguzhan (Chairman and CEO) sold 32,500 shares of BillionToOne, Inc. (BLLN) at an average of $136.95 ($133.00–$139.21, $4.45M total) across 21 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readBillionToOne, Inc. (BLLN): Results of Operations and Financial Condition
BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al
7 min readSakakibara Shan Riku sold $561K of BLLN
Sakakibara Shan Riku (Chief Product Officer) sold 4,000 shares of BillionToOne, Inc. (BLLN) at $140.21 ($0.56M total) on 2026-07-31 under a Rule 10b5-1 trading plan.
1 min read